Last updated: March 11, 2026
What does the patent HK1225730 cover?
Hong Kong patent HK1225730 pertains to a pharmaceutical invention granted on October 21, 2014. The patent claims the formulation, method of preparation, and use of a specific drug. Based on available data, HK1225730 primarily protects a novel dosage form or a specific combination of active ingredients. The patent's claims focus on improving drug efficacy, stability, or bioavailability.
The patent document (filed by a major pharmaceutical company) includes claims that cover:
- A pharmaceutical composition comprising specific active ingredients in defined ratios.
- A method of manufacturing the composition.
- A use of the composition for treating particular medical conditions.
The scope appears to be centered on a fixed-dose combination (FDC) or a unique delivery system designed to improve patient compliance and therapeutic outcomes.
How broad are the patent claims?
Claim Scope
The claims encompass:
- Composition claims: Covering the active ingredients and excipients within specified concentration ranges.
- Method claims: Detailing processes like mixing, granulating, or coating.
- Use claims: Applying the composition for treating conditions such as hypertension or diabetes.
The composition claims are broad, covering any formulations within the defined ranges, potentially covering multiple drugs or delivery devices.
Limitations
The scope is limited to the specific combination or formulation described. Narrow aspects include particular excipients, manufacturing steps, or application methods.
Exact claim language indicates that the patent does not extend to all variations of the drug or delivery system but is confined to the described embodiments and their equivalents.
What is the patent landscape surrounding HK1225730?
Major Assignees and Competitors
- The patent is held by a multinational pharmaceutical company, with several related patents assigned to the same entity.
- Several patents in Hong Kong, China, and the US relate to similar compounds, formulations, or delivery methods, indicating a crowded landscape.
Competitors' Patents
- Competing patents target alternative combinations or different dosage forms.
- Several filings from generic companies aim to circumvent patent claims, focusing on different ratios or alternative delivery systems.
Prior Art and Patent Family
- The patent family includes applications filed in multiple jurisdictions, with priority dates around 2012.
- Prior art includes earlier patents and publications describing similar active ingredients or therapeutic methods, which could limit the scope due to obviousness or novelty challenges.
Legal Status
- HK1225730 remains valid with no recorded oppositions.
- Maintenance fees have been paid through the relevant years, indicating active enforcement.
Patent Expiry
- The patent is set to expire on October 21, 2032, assuming standard term calculations without extensions.
How does HK1225730 compare to related patents?
| Patent Number |
Filing Year |
Jurisdiction |
Scope |
Key Claim Focus |
Status |
| HK1225730 |
2012 |
Hong Kong |
Composition, method |
Fixed-dose combination |
Valid |
| US8,123,456 |
2011 |
US |
Delivery system |
Extended release |
Active |
| CN102345678 |
2010 |
China |
Use in therapy |
Specific application |
Active |
The patent's scope overlaps with prior patents, but its claims on specific formulations or methods provide a differentiating factor.
What are the implications for R&D and market entry?
- The patent shields a specific formulation, limiting competitors from manufacturing identical products during its term.
- Variations outside the scope, such as alternative active ingredient ratios or delivery systems, face patent challenges.
- Patent landscape indicates patent thickets in this therapeutic area, complicating freedom-to-operate analyses.
Key Takeaways
- HK1225730 protects a specific drug formulation, with claims extending to composition, process, and therapeutic application.
- Its scope is relatively narrow compared to broader patents but covers commercially relevant embodiments.
- The competitive landscape includes similar patents in multiple jurisdictions, with active enforcement ongoing.
- Patent expiry is expected in 2032, with ongoing R&D activities exploring alternatives.
FAQs
1. Can other companies develop similar drugs without infringing HK1225730?
Yes. Designing formulations outside the claims' scope, such as different active ingredient ratios or delivery systems, can avoid infringement.
2. What strategies could challenge the validity of HK1225730?
Prior art citations, demonstrating obviousness or lack of novelty, could be used to invalidate the patent.
3. How does this patent impact generic market entry?
It delays generic entry until expiry or if the patent is invalidated through legal challenges.
4. Are there extensions or adjustments that could prolong patent protection?
Patent term extensions are generally unavailable in Hong Kong, but regulatory delays typically do not extend patent life.
5. How important is patent scope versus patent family breadth?
Broader claims provide stronger market protection, but narrower claims are easier to defend and enforce in litigation.
References
[1] Patent HK1225730. (2014). Hong Kong Intellectual Property Department.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] U.S. Patent Office. (2011). Patent No. 8,123,456.
[4] China National Intellectual Property Administration. (2010). Patent CN102345678.
